Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Inclusion Criteria: * Subjects ≥ 18 years of age who have signed informed consent * Philadelphia positive Chronic Myeloid Leukemia (CML) in chronic phase * Previously untreated chronic phase CML, except for Anagrelide or Hydroxyurea. * Eastern Co-Operative Group (ECOG) Performance Status (PS) Score 0 - 2 Exclusion Criteria: * Known Abl-kinase T315I or T315A mutation * Serious or uncontrolled medical disorder (including infection or cardiovascular disease) or dementia or other serious psychiatric condition * Prior chemotherapy. * Women who are pregnant or breastfeeding or Women of Child Bearing Potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy during the entire study period.